Journal of Microbiology and Biotechnology
The Korean Society for Microbiology and Biotechnology publishes the Journal of Microbiology and Biotechnology.
Journal of Microbiology and Biotechnology
Condition  Expression
When you enter More than two words, please use ‘and , or’ operation by means of putting ‘,(Comma Mark)’ between each word.

2013 ; 23(3): 322~328

AuthorHyun Kang, Micheal B. Ye, Young Yil Bahk
AffiliationDepartment of Biotechnology College of Biomedical and Health Science, Konkuk University, Chungju-City, 380-701, Korea
TitleExpression and Purification of Human Farnesoid X Receptor-Ligand Binding Domain as Soluble Form Using a Dual Cistronic Expression Vector
PublicationInfo J. Microbiol. Biotechnol.2013 ; 23(3): 322~328
AbstractIn this study, we show the expression and purification of the human recombinant farnesoid X receptor (FXR)- ligand binding domain (LBD) protein in E. coli using a double cistronic vector, pACYCDuet-1, as a soluble form. We describe here the expression and characterization of a biologically active FXR-LBD(248-476). When expressed in the influence of bacterial promoters (PT7 and PTac) of the single cistronic expression vectors, the human recombinant FXR-LBD(248-476) was found to be totally insoluble. However, by using a double cistronic expression vector, we were able to obtain the human recombinant FXR-LBD(248-476) in a soluble form. To allow for biological activities, we have subcloned into the pACYCDuet-1 vector, expressed in E. coli cells at some optimized conditions, and purified and characterized the human recombinant active FXR-LBD(248-476) proteins using the fluorescence polarization assay. This suggests that the expression of FXR-LBD in a double cistronic vector improves its solubility and probably assists its correct folding for the biologically active form of the proteins. We suggest that this may represent a new approach to high expression of other nuclear receptors and may be useful as well for other classes of heterodimeric protein partners.
Full-Text(PDF)
KeywordsNuclear receptor, Recombinant FXR-LBD, Dual expression vector, E.coli expression system
References
  1. Altucci, L., M. D. Leibowitz, K. M. Ogilvie, A. R. de Leva, and H. Gronemeyer. 2007. RXR and RXR modulation in cancer and metabolic disease. Nat. Rev. Drug Discov. 6: 793-810.
    Pubmed CrossRef
  2. Aranda, A. and A. Pascual. 2001. Nuclear hormone receptors and gene expression. Physiol. Rev. 81: 1269-1304.
    Pubmed
  3. Bourguet, W., M. Ruff, P. Chambon, H. Gronemeyer, and D. Moras. 1995. Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α. Nature 375: 377-382.
    Pubmed CrossRef
  4. Dagher, R., C. Pigault, D. Bonnet, D. Boeglin, C. Pourbaix, M. C. Kilhoffer, et al. 2006. Use of a fluorescence polarization based high throughput assay to identify new calmodulin ligands. Biochim. Biophys. Acta 1763: 1250-1255.
    Pubmed CrossRef
  5. Fuchs, M. 2012. Non-alcoholic fatty liver disease: The bile acid-activated farnesoid X receptor as an emerging treatment target. J. Lipids DOI:10.1155/2012/934396.
    CrossRef
  6. Gadaleta, R. M., K. J. van Erpecum, B. Oldenburg, E. C. Willemsen, W. Renooij, S. Murzilli, et al. 2011. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 60: 463-472.
    Pubmed CrossRef
  7. Hollman, D. A. A., A. Miloan, K. J. van Erpecum, and S. W. van Mil. 2012. Anti-inflammatory and metabolic actions of FXR: Insights into molecular mechanism. Biochem. Biophys. Acta 1821: 1443-1452.
    Pubmed CrossRef
  8. Jonker, J. W., C. Liddle, and M. Downes. 2012. FXR and PXR:Potential therapeutic targets in cholestasis. J. Steroid Biochem. Mol. Biol. 130: 147-158.
    Pubmed CrossRef
  9. Lafebvre, P., B. Cariou, F. Lien, F. Kuipers, and B. Staels. 2009. Role of bile acids and bile acid receptors in metabolic regulation. Physiol. Rev. 89: 147.
    Pubmed CrossRef
  10. Laffitte, B. A., H. R. Kast, C. M. Nguyen, A. M. Zavacki, D. D. Moore, and P. A. Edwards. 2000. Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor. J. Biol. Chem. 275: 10638-10647.
    Pubmed CrossRef
  11. Lee, K. C. and W. L. Kraus. 2001. Nuclear receptors, coactivators and chromatin: New approaches, new insights. Trends Endocrinol. Metab. 12: 191-197.
    CrossRef
  12. Lévy-Bimbot, M., G. Major, D. Courilleau, J. P. Blondeau, and Y. Levi. 2012. Tetrabromobisphenol-A disrupts thyroid hormone receptor A function in vitro: Use of fluorescence polarization to assay corepressor and coactivator peptide binding. Chemosphere 87: 782-788.
    Pubmed CrossRef
  13. Li, C., J. W. Schwabe, E. Banayo, and R. M. Evans. 1997. Coexpression of nuclear receptor partners increases their solubility and biological activities. Proc. Natl. Acad. Sci. USA 94: 2278-2283.
    Pubmed CrossRef Pubmed Central
  14. Lu, T. T., M. Makishima, J. J. Repa, K. Schoonjans, T. A. Kerr, J. Auwerx, and D. J. Mangelsdorf. 2000. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol. Cell 6: 507-515.
    CrossRef
  15. Makishima, M., A. Y. Okamoto, J. J. Repa, H. Tu, R. M. Leaned, A. Luk, et al. 1999. Identification of a nuclear receptor for bile acids. Science 284: 1362-1365.
    Pubmed CrossRef
  16. Mangelsdorf, D. J. and R. M. Evans. 1995. The RXR heterodimers and orphan receptor. Cell 83: 841-850.
    CrossRef
  17. Mangelsdorf, D. J., C. Thummel, M. Beato, P. Herrich, G. Schultz, K. Umesono, et al. 1995. The nuclear receptor superfamily: The second decade. Cell 83: 835-839.
    CrossRef
  18. McKenna, N. J., R. B. Lanz, and B. W. O’Malley. 1999. Nuclear receptor coregulators: Cellular and molecular biology. Endocrinol. Rev. 20: 321-344.
    CrossRef
  19. Nagy, L. and J. W. R. Schwabe. 2004. Mechanism of the nuclear receptor molecular switch. Trends Biochem. Sci. 29:317-324.
    Pubmed CrossRef
  20. Neuschwander-Tetri, B. A. 2012. Farnesoid X receptor agonists:What they are and how they might be used in treating liver disease. Curr. Gastroenterol. Rep. 14: 55-62.
    Pubmed CrossRef
  21. Ogawa, S., J. Lozach, C. Benner, G. Pascual, R. K. Tangirala, S. Westin, et al. 2005. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 122:707-721.
    Pubmed CrossRef Pubmed Central
  22. Overington, J. P. and B. Al-Lazikani. 2006. How many drug targets are there? Nat. Rev. Drug Discov. 5: 993-996.
    Pubmed CrossRef
  23. Parks, D. J., S. G. Blanchard, R. K. Bledsoe, G. Chandra, T. G. Consler, S. A. Kliewer, et al. 1999. Bile acids: Natural ligands for orphan nuclear receptor. Science 284: 1365-1358.
    Pubmed CrossRef
  24. Saïda, F., M. Uzan, B. Odaert, and F. Bontems. 2006. Expression of highly toxic genes in E. coli: Special strategies and genetic tools. Curr. Protein Pept. Sci. 7: 47-56.
    Pubmed CrossRef
  25. Seol, W., H. S. Choi, and D. D. Moore. 1995. Isolation of proteins that interact specifically with the retinoid X receptor:Two novel orphan receptors. Mol. Endocrinol. 9: 72-85.
    Pubmed CrossRef
  26. Sørensen, H. P. and K. K. Mortensen. 2005. Advanced genetic strategies for recombinant protein expression in Escherichia coli. J. Biotechnol. 115: 113-128.
    Pubmed CrossRef
  27. Teodoro, J. S., A. P. Rolo, and C. M. Plameira. 2011. Hepatic FXR: Key regulator of whole-body energy metabolism. Trends Endocrinol. Metab. 22: 458-466.
    Pubmed CrossRef
  28. Thomas, A. M., S. N. Hart, B. Kong, J. Fang, X. B. Zhong, and G. L. Guo. 2010. Genome-wide tissue-specific farnesoid X receptor binding in mouse liver and intestine. Hepatology 51:1410-1419.
    Pubmed CrossRef
  29. Vavassori, P., A. Mencarelli, B. Renga, E. Distrutti, and S. Fiorucci. 2009. The bile acid receptor FXR is a modulator of intestinal innate immunity. J. Immunol. 183: 6251-6261.
    Pubmed CrossRef
  30. Wurtz, J. M., W. Bourguet, J. P. Renaud, V. Vivat, P. Chambon, D. Moras, and H. Gronemeyer. 1996. A canonical structure for the ligand-binding domain of nuclear receptors. Nat. Struct. Mol. Biol. 3: 87-94.
    CrossRef
Copyright © 2009 by the Korean Society for Microbiology and Biotechnology.
All right reserved. Mail to jmb@jmb.or.kr
Online ISSN: 1738-8872    Print ISSN: 1017-7825    Powered by INFOrang.co., Ltd